Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(7):496-497; doi:10.1093/jnci/djk129
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Parekh, D. J.
Right arrow Articles by Thompson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parekh, D. J.
Right arrow Articles by Thompson, I. M.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Prostate-Specific Antigen Levels, Prostate-Specific Antigen Kinetics, and Prostate Cancer Prognosis: A Tocsin Calling for Prospective Studies

Dipen J. Parekh, Donna P. Ankerst, Ian M. Thompson

Affiliation of authors: Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX

Correspondence to: Dipen J. Parekh, MD, Department of Urology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 (e-mail: parekhd@uthscsa.edu).

The first 10% of the full text of this article appears below.

In 1985, a US man had an 8.7% lifetime risk of receiving a diagnosis of prostate cancer and a 2.5% risk in his life of death from the disease; these two risks today are 17% and 3%, respectively (1,2). Prostate-specific antigen (PSA) screening is largely responsible for this increase in diagnosis; its contribution to the 31% fall in mortality between 1990 and 2003 remains a subject of heated debate (2). Along with the substantial increase in detection of the disease has been a concomitant stage migration from tumors of high volume and grade to tumors of lower volume and grade—and presumably of lower biologic potential.

Recognizing . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer
Katja Fall, Hans Garmo, Ove Andrén, Anna Bill-Axelson, Jan Adolfsson, Hans-Olov Adami, Jan-Erik Johansson, and Lars Holmberg
J Natl Cancer Inst 2007 99: 526-532. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 493. [Extract] [Full Text] [PDF]

Press Release: PSA Is Poor Predictor of Lethal Prostate Cancer
Liz Savage
J Natl Cancer Inst 2007 99: 493. [Extract] [Full Text]